Regulatory Information
HSA regulatory responsibility and product classification details
Regulatory Responsibility
Product Classification
Formulation Information
TABLET, SUGAR COATED
**Dosage and method of administration** Dosage _Adults_ 300–600 mg daily in three or four divided doses. _Children_ Perazodin is not recommended for children. Method of administration Oral administration. Perazodin should usually be taken before meals.
ORAL
Medical Information
**Indications** An adjunct to oral anti-coagulation for prophylaxis of thrombo-embolism associated with prosthetic heart valves.
**Contraindications** Hypersensitivity to the active substance(s) or to any of the excipients listed in section List of excipients – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. In case of rare hereditary conditions that may be incompatible with an excipient of the product (please refer to section Warnings and Precautions – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_) the use of the product is contraindicated.
B01AC07
dipyridamole
Manufacturer Information
GOLDPLUS UNIVERSAL PTE LTD
REMEDICA LTD
Active Ingredients
Documents
Package Inserts
Perazodin Tablet PI.pdf
Approved: December 21, 2022